JP2023511472A5 - - Google Patents
Info
- Publication number
- JP2023511472A5 JP2023511472A5 JP2022525186A JP2022525186A JP2023511472A5 JP 2023511472 A5 JP2023511472 A5 JP 2023511472A5 JP 2022525186 A JP2022525186 A JP 2022525186A JP 2022525186 A JP2022525186 A JP 2022525186A JP 2023511472 A5 JP2023511472 A5 JP 2023511472A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- linker
- hydrogen
- existence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962927340P | 2019-10-29 | 2019-10-29 | |
| US62/927,340 | 2019-10-29 | ||
| EP19209344.1 | 2019-11-15 | ||
| EP19209344 | 2019-11-15 | ||
| PCT/EP2020/080265 WO2021083949A1 (en) | 2019-10-29 | 2020-10-28 | Bifunctional compounds for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023511472A JP2023511472A (ja) | 2023-03-20 |
| JP2023511472A5 true JP2023511472A5 (https=) | 2023-11-01 |
Family
ID=73020226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525186A Pending JP2023511472A (ja) | 2019-10-29 | 2020-10-28 | がんの治療のための二官能性化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230024096A1 (https=) |
| EP (1) | EP4051674A1 (https=) |
| JP (1) | JP2023511472A (https=) |
| CN (1) | CN114728936A (https=) |
| WO (1) | WO2021083949A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2021126973A1 (en) * | 2019-12-17 | 2021-06-24 | Orionis Biosciences, Inc. | Compounds modulating protein recruitment and/or degradation |
| WO2021133917A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| EP4081308A4 (en) | 2019-12-23 | 2024-01-24 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| KR20230005160A (ko) | 2020-03-19 | 2023-01-09 | 카이메라 쎄라퓨틱스 인코포레이티드 | Mdm2 분해제 및 이의 용도 |
| WO2021207291A1 (en) * | 2020-04-06 | 2021-10-14 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| IL300397A (en) | 2020-08-05 | 2023-04-01 | C4 Therapeutics Inc | Compounds for targeted knockdown of RET |
| EP4259144A4 (en) * | 2020-12-09 | 2025-08-20 | Kymera Therapeutics Inc | SMARCA DEGRADING AGENTS AND THEIR USES |
| KR20240004983A (ko) * | 2021-05-10 | 2024-01-11 | 포그혼 쎄라퓨틱스 인크. | 화합물 및 이의 용도 |
| CA3219183A1 (en) | 2021-05-17 | 2022-11-24 | Amedeo Caflisch | N6-adenosine-methyltransferase inhibitors in cancer treatment |
| US20240358842A1 (en) * | 2021-06-25 | 2024-10-31 | Stablix, Inc. | Protein stabilizing compounds containing usp7 ligands |
| US20250018046A1 (en) * | 2021-07-07 | 2025-01-16 | Biogen Ma Inc | Compounds for targeting degradation of irak4 proteins |
| KR20240046498A (ko) | 2021-08-09 | 2024-04-09 | 제넨테크, 인크. | Brm의 조절에 사용하기 위한 페놀 유도체 |
| WO2023039573A1 (en) * | 2021-09-10 | 2023-03-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Compounds for targeted degradation of taf1 |
| CN117384161A (zh) * | 2022-07-04 | 2024-01-12 | 华东理工大学 | 靶向降解cdk蛋白的化合物及其应用 |
| WO2024026083A1 (en) * | 2022-07-29 | 2024-02-01 | Ribon Therapeutics, Inc. | Targeted protein degradation of parp14 for use in therapy |
| WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
| CN116120311B (zh) * | 2022-11-28 | 2025-10-24 | 中国药科大学 | 一种靶向降解atr蛋白的双功能化合物及其制法与用途 |
| CN116284202B (zh) * | 2023-03-28 | 2024-07-02 | 华侨大学 | 白桦脂酸的PROTACs化合物及其制备方法和应用 |
| WO2024213125A1 (zh) * | 2023-04-14 | 2024-10-17 | 南京再明医药有限公司 | Brm选择性降解剂及其应用 |
| TW202502750A (zh) | 2023-06-08 | 2025-01-16 | 美商新銳思生物製藥股份有限公司 | Smarca2之雙官能選擇性降解劑及其治療用途 |
| PE20260301A1 (es) * | 2023-06-14 | 2026-02-10 | Astrazeneca Ab | Derivados de 3-[3-amino-6-(2-hidroxifenil)piridazin-4-il]-3,8-diazabiciclo[3.2.1]octano como protacs degradantes de smarca2 para el tratamiento del cancer |
| WO2025006902A2 (en) * | 2023-06-29 | 2025-01-02 | Dana-Farber Cancer Institute, Inc. | Synthesis and in vitro characterization of proteolysis targeting chimeras (protacs) for degradation of dna methyltransferase 1 (dnmt1) |
| WO2025061035A1 (zh) * | 2023-09-19 | 2025-03-27 | 南京再明医药有限公司 | Brm选择性降解剂化合物及其应用 |
| WO2025094065A1 (en) | 2023-11-01 | 2025-05-08 | Aurigene Oncology Limited | Amino-substituted pyridazine compounds as smarca2 and/or smarca4 degraders |
| WO2026061475A1 (zh) * | 2024-09-19 | 2026-03-26 | 标新生物医药科技(上海)有限公司 | 含有芳基取代杂芳基的双功能蛋白降解剂及其应用 |
| CN119798218A (zh) * | 2024-12-31 | 2025-04-11 | 南京优氟医药科技有限公司 | 一种e3酶配体-连接链复合物及其制备方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US533A (en) | 1837-12-26 | Truss for hermta | ||
| US4943A (en) | 1847-01-26 | Harness-buckle | ||
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DE69428764T2 (de) | 1993-12-24 | 2002-06-20 | Merck Patent Gmbh | Immunokonjugate |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| WO1996003397A1 (en) | 1994-07-21 | 1996-02-08 | Akzo Nobel N.V. | Cyclic ketone peroxide formulations |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| SI9620103A (sl) | 1995-07-06 | 1998-10-31 | Novartis Ag | Pirolopirimidini in postopki za njihovo pripravo |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| EA001595B1 (ru) | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO1998050038A1 (en) | 1997-05-06 | 1998-11-12 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| BR9814116A (pt) | 1997-11-06 | 2000-10-03 | American Cyanamid Co | Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico |
| EA003786B1 (ru) | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ |
| JP6759514B2 (ja) * | 2014-08-01 | 2020-09-23 | ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ | ブロモドメインに対して活性な化合物 |
| CN107074824B (zh) * | 2014-09-05 | 2021-01-08 | 基因泰克公司 | 作为用于治疗癌症的pcaf和gcn5抑制剂的式(i)的酞嗪衍生物 |
| US9694084B2 (en) * | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2016105518A1 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| US20190300521A1 (en) * | 2018-04-01 | 2019-10-03 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| EP3784665A4 (en) * | 2018-04-26 | 2022-01-26 | Aurigene Discovery Technologies Limited | PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS |
| US11771697B2 (en) * | 2018-04-30 | 2023-10-03 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of polybromo-1 (PBRM1) |
| WO2020010227A1 (en) * | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US20230072658A1 (en) * | 2019-06-10 | 2023-03-09 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2020251969A1 (en) * | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
-
2020
- 2020-10-28 JP JP2022525186A patent/JP2023511472A/ja active Pending
- 2020-10-28 WO PCT/EP2020/080265 patent/WO2021083949A1/en not_active Ceased
- 2020-10-28 US US17/771,204 patent/US20230024096A1/en active Pending
- 2020-10-28 EP EP20797473.4A patent/EP4051674A1/en not_active Withdrawn
- 2020-10-28 CN CN202080076232.9A patent/CN114728936A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023511472A5 (https=) | ||
| JP2023511471A5 (https=) | ||
| Tittal et al. | Design, synthesis, biological activity, molecular docking and computational studies on novel 1, 4-disubstituted-1, 2, 3-Triazole-Thiosemicarbazone hybrid molecules | |
| Jopp et al. | Anticancer activity of a series of copper (II) complexes with tripodal ligands | |
| EP0471709B1 (en) | Ruthenium(iii) complexes as antineoplastic agents | |
| Koch et al. | Synthesis, characterization, and biological properties of steroidal ruthenium (II) and iridium (III) complexes based on the androst-16-en-3-ol framework | |
| Yousef et al. | Benzohydrazide derivative metal complex's antimicrobial and inhibitory effects on liver cancer cell lines and quinone oxidoreductase 2: Experimental, molecular docking, and DFT investigations | |
| Crabtree | Some chelating C-donor ligands in hydrogen transfer and related catalysis | |
| JP5769831B2 (ja) | イソホスホルアミドマスタードおよびその類似体の合成および製剤 | |
| JP2010523571A5 (https=) | ||
| DeBord et al. | Synthesis, characterization, and in vitro SAR evaluation of N, N′-bis (arylmethyl)-C2-alkyl substituted imidazolium salts | |
| KR20120123279A (ko) | 항암제 | |
| NZ535366A (en) | Substituted tetrahydroisoquinoline compounds, methods of making, and their use | |
| AU716220B2 (en) | New salts of anionic complexes of RU(III), as antimetastatic and antineoplastic agents | |
| Mu et al. | Ruthenium anticancer compounds with biologically‐derived ligands | |
| RU2024136909A (ru) | Соединения для направленной деградации smarca2 | |
| Barbanente et al. | New oxaliplatin-zoledronate derivatives with potential antitumor activity towards bone tumors and metastases | |
| CA2458476C (en) | Photoreactive compounds and compositions | |
| TW393488B (en) | Process for making 1-hydrox-ybisphosphonates | |
| WO2019110006A1 (zh) | 抗疼痛化合物及其制备方法 | |
| JP2021523936A (ja) | 金（ｉｉｉ） 錯体、金（ｉｉｉ） 錯体のコンジュゲート、金（ｉｉｉ） 錯体を含む医薬組成物、金（ｉｉｉ） 錯体を生成する方法とその使用。 | |
| JP5746693B2 (ja) | セレノキノン由来の活性有機金属錯体、該錯体の製造方法、および、該錯体の用途 | |
| KR100378257B1 (ko) | 비스카르복시에틸게르마늄 세스퀴옥사이드-전이금속착화합물 및 이를 유효성분으로 함유하는 새로운 항종양제 | |
| Dahm | Metallocarbenes for therapeutic applications | |
| US7390915B1 (en) | Phosphine transition metal complex having ferrocene skeleton, process for making the same, and anti-cancer agent |